aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2024. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Immune-Onc Therapeutics, Inc., founded in California, is a clinical-stage biopharmaceutical company dedicated to developing therapeutic antibodies for cancer treatment. The company's core mission is to advance the field of cancer immunotherapy by creating innovative treatments that harness the body's immune system to fight cancer. Their product pipeline focuses on addressing unmet medical needs in immunology and inflammation, blood cancers, and solid tumors.
Notable affiliated individuals include experts in oncology and immunotherapy, contributing to the company's robust research and development efforts. Immune-Onc Therapeutics has attracted significant investment from leading venture capital firms, underscoring confidence in its potential. Key achievements include progressing multiple candidates through clinical trials, demonstrating promising efficacy and safety profiles. The company's impact lies in its potential to offer new hope to cancer patients through cutting-edge immunotherapeutic solutions.
Operating Status
Active
Ownership Type(s)
Public
Main Product(s)
Cancer Treatment
Technology
Biotech
Tags
Healthtech
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
United States
When was Immune-Onc Therapeutics founded?
Immune-Onc Therapeutics was founded in 2016.
Where is Immune-Onc Therapeutics’s headquarters located?
Immune-Onc Therapeutics’s headquarters is located in Palo Alto, CA, US.
When was Immune-Onc Therapeutics’s last funding round?
Immune-Onc Therapeutics’s most recent funding round was for $25M (USD) in January 2023.
How many employees does Immune-Onc Therapeutics have?
Immune-Onc Therapeutics has 35 employees as of Feb 5, 2024.
How much has Immune-Onc Therapeutics raised to-date?
As of July 05, 2023, Immune-Onc Therapeutics has raised a total of $140.1M (USD) since Jan 5, 2023.
Add Comparison
Total Raised to Date
$140.1M
USD
Last Update Jan 5, 2023
Last Deal Details
$25M
USD
Jan 5, 2023
Series B
Total Employees Over Time
35
As of Feb 2024
Immune-Onc Therapeutics Address
1059 E Meadow Cir.
Palo Alto,
California
94303
United States of America
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts